Targeted radionuclide therapy enhances prostate cancer response to immunotherapies

Targeted radionuclide therapy enhances prostate cancer response to immunotherapies

Press releases may be edited for formatting or style | July 13, 2020 Molecular Imaging

The study also presents a paradigm change in targeted radionuclide therapy, where the maximum tolerable dose may not always be the most beneficial to patients. "A key finding of our work is that immunomodulation is best achieved with a relatively low radiation dose to the tumor which does not affect the normal immune system," Hernandez noted. "As high radiation doses to normal lymphoid organs can negate the benefits of immunomodulation, estimating the radiation doses imparted to the tumor and normal tissues prospectively by using patient-specific image-based dosimetry techniques is critical. This means that, essentially, a theranostic approach must be implemented."

Abstract 36. "Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy," Reinier Hernandez, Hemanth Potluri, Eduardo Aluicio-Sarduy, Joseph Grudzinski, Christopher Massey, Christopher Zahm, Jonathan Engle, Douglas McNeel and Jamey Weichert, University of Wisconsin-Madison, Madison, Wisconsin. SNMMI's 67th Annual Meeting, July 11-14, 2020.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI's members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.

Back to HCB News

You Must Be Logged In To Post A Comment